二肽基肽酶Ⅳ（DPP-4）抑制剂是近年来新上市的一种新型口服降糖药物。 DPP-4抑制剂通过抑制DPP-4来抑制胰岛素多肽（GIP）和胰高血糖素样肽1（GLP-1）降解，发挥降低血糖的作用。 DPP-4抑制剂不仅能双向控制血糖，且具有降糖外的胰腺、心血管、肾脏、肝脏等多器官保护作用和抗炎作用。本文对已有的DPP-4抑制剂及其多器官保护作用进行综述，总结其优势及进一步发展的趋势，为临床用药提供参考。%Dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a new type of oral antidiabetic drugs appeared in recent years, which provides new approaches for the treatment of type 2 diabetes. DPP-4 inhibitors currently include five drugs as sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin. Most animal experiments and clinical trials proved that DPP-4 inhibitors could not only control blood sugar bidirectionally, but also show positive effects on organs like pancreas, cardiovas_cular, kidney and liver. This article summarizes the knowledge of DPP-4 inhibitor and their multi-organ protective effects, to show the advantages and further development trends, and to provide reference for clinical use.
展开▼
